



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Laser Interstitial Thermal Therapy (LITT) for Neurological Disorders

Policy #: 728

Latest Review Date: December 2022

Category: Surgery

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

For dates of service on or after January 1, 2022:

Epilepsy

Blue Advantage will treat **laser interstitial thermal therapy (LITT)** (e.g., the NeuroBlate and the Visualase Thermal Therapy System) as a **covered benefit** as a treatment of refractory epilepsy when ALL of the following conditions have been met:

- Non-epileptic attacks such as cardiogenic syncope and psychogenic seizures have been ruled out.
- The diagnosis of epilepsy has been documented, and the epileptic seizure type and syndrome has been clearly defined.
- Documented disabling seizures, despite the use of two or more tolerated antiepileptic drug regimens (i.e., medically refractory epilepsy).
- There is a well-defined epileptogenic focus in the temporal lobe or hypothalamus accessible by LITT.

Radiation Necrosis

Blue Advantage will treat **laser interstitial thermal therapy (LITT)** (e.g., the NeuroBlate and the Visualase Thermal Therapy System) as a **covered benefit** as a treatment for medically refractory radiation necrosis with lesions not amenable to surgical decompression or refractory radiation necrosis despite prolonged, high-dose steroid therapy.

Blue Advantage will treat **laser interstitial thermal therapy (LITT)** as a **non-covered benefit** and as **investigational** for all other indications.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Laser Interstitial Thermal Therapy (LITT)

Epilepsy

Laser interstitial thermal therapy (LITT) utilizes thermal energy to induce cell death by damaging DNA and triggering protein denaturation. This technique uses heat to target and ablate the region where the seizure begins. This minimally invasive procedure offers alternatives to patients who are not optimal candidates for open resection.

Laser interstitial thermal therapy (LITT) minimizes injury to surrounding brain because it is done through a burr hole. This technology lowers the risk of affecting normal neurological function,

endorses less operative risk, less discomfort, and shorter hospitalizations. Laser Interstitial Thermal Therapy (LITT) is FDA approved for soft tissue ablation and is increasingly utilized to treat epilepsy, especially when seizures arise from deeper structures such as the hippocampus, amygdala, or discrete dysplastic tissue, such as hypothalamic hamartomas. Mesial temporal epilepsy is the most frequently encountered surgically remedial epilepsy suitable for LITT, particularly when there is unilateral hippocampal sclerosis. There is emerging evidence that it can be effective for eliminating seizures in this type of epilepsy, and that it has a lower risk of cognitive deficits than anterior temporal lobectomy.

Radiation Necrosis

Radiation Necrosis, or treatment-induced brain tissue necrosis, is a serious complication that usually develops one to three years after radiation. The dose that causes necrosis may vary by region of the brain. Tissue necrosis is more likely to occur when high doses per fraction are given with concurrent chemotherapy or radio sensitizers. The risk of tissue necrosis after stereotactic radiosurgery (SRS) has been reported to be higher, with a steep dose-response relationship. Tissue necrosis develops at or nearby the original site of the tumor, or the location that received the highest radiation dose. Tissue necrosis can also develop in part of the normal brain parenchyma that was included in the treatment field, such as temporal lobe necrosis that develops in some patients treated for nasopharyngeal cancer or clival chordoma. In this setting, brain tissue necrosis typically presents as new focal neurologic signs, and imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI) may show an enhancing mass lesion with edema.

The clinical course of brain tissue necrosis is highly variable. Management is primarily symptomatic. The treatment requires a balance between the competing goals of symptom control and avoidance of side effects. In some cases, tissue necrosis is an asymptomatic, self-limited process that can be managed conservatively without intervention. In patients who are symptomatic, initial treatment includes a moderate dose of an oral glucocorticoid, which usually produces prompt symptomatic improvement by reducing cerebral edema. Once symptoms are controlled, glucocorticoids can then be gradually tapered. Follow-up imaging after one to two months is recommended.

For patients who do not achieve symptomatic response to glucocorticoids, or when glucocorticoids cannot be tapered without the reoccurrence of symptoms, surgical resection of the necrotic tissue is sometimes required. Surgery can provide palliative benefit by reducing mass effect and decreasing steroid requirements postoperatively. Minimally invasive laser interstitial thermal therapy (LITT) has been explored as therapeutic intervention in the treatment of radiation necrosis.

KEY POINTS:

Updated searches of the MEDLINE database have been performed, most recently conducted through November 14, 2022.

Summary of Evidence

Laser interstitial thermal therapy (LITT) may be an alternative treatment option for high-risk surgical patients. This minimally invasive approach is considered favorable due to evidence showing fewer complications, reduced length of procedure time, decreased hospitalization time, and a reduction in analgesic requirement when compared to open surgery. The current studies suggest that future research should continue in order to understand the long-term outcomes associated with resection versus laser ablation surgery.

Practice Guidelines and Position Statements

American Association of Neurological Surgeons et al

In September 2021, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Joint Section on Tumors issued a position statement regarding the use of laser interstitial thermal therapy (LITT) for brain tumors and radiation necrosis. The statement concludes that "LITT is an appealing option because it offers a method of minimally invasive, targeted thermal ablation of a lesion with minimal damage to healthy tissue. There is a growing body of evidence to demonstrate that LITT is an effective and well-tolerated cytoreductive option for treatment of [newly diagnosed glioblastoma multiforme (GBM), recurrent GBM, and primary or recurrent brain metastases.] Intracranial LITT is also an effective option for addressing radiation necrosis with an overall reduction in steroid dependence for these patients. Especially in instances where the therapeutic window is narrowed such that craniotomy is not a viable option, LITT can play an important role in treatment for glioma or metastatic brain cancer."

American Society for Stereotactic and Functional Neurosurgery

In September 2021, the American Society for Stereotactic and Functional Neurosurgery (ASSFN) issued a position statement on the use of LITT in drug-resistant epilepsy. The statement recommends consideration of MR-guided LITT (MRgLITT) as a treatment option when all of the following criteria are met: "Failure to respond to, or intolerance of, at least 2 appropriately chosen medications at appropriate doses for disabling, localization-related epilepsy AND Well-defined epileptogenic foci or critical pathways of seizure propagation accessible by MRgLITT."

The Congress of Neurological Surgeons

In 2019, the Congress of Neurological Surgeons completed a systematic review and evidence-based guideline on the role of emerging and investigational therapies for the treatment of adults with metastatic brain tumors. Brain metastases associated with systemic cancer remain challenging to treat. Current standard treatment modalities, including surgery and radiation, cannot be applied to all patients and are not uniformly successful when applied. Therefore, novel treatment strategies are necessary.

The National Comprehensive Cancer Network (NCCN)

The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for central nervous system cancers (v.2.2022) states that magnetic resonance (MR) guided LITT "may be considered for patients who are poor surgical candidates (craniotomy or resection). Potential

indications include relapsed brain metastases, radiation necrosis, and recurrent glioblastoma." (Category 2B) The guidelines additionally state that LITT "can be considered on a case-by-case basis for treatment of radiation necrosis in patients with a history of radiation therapy for primary brain tumor or metastatic disease. Consultation with adept neurosurgeons trained in LITT should be done when the procedure is considered."

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Epilepsy Surgery, laser interstitial thermal therapy; LITT; MR-guided stereotactic laser amygdalohippocampotomy; MRgLITT; NeuroBlate; Visualase; thermal therapy; mesial temporal lobe epilepsy; MTLE; focal laser therapy, interstitial laser ablation, interstitial laser coagulation, interstitial laser photocoagulation, laser induced thermal therapy, MRI-guided laser interstitial thermal therapy (MRgLITT) and photothermal therapy.

APPROVED BY GOVERNING BODIES:

In August 2007, the Visualase™ MRI-Guided Laser Ablation System Thermal Therapy System (Medtronic; formerly Biotex, Inc.) received initial marketing clearance by the U.S. Food and Drug Administration (FDA) through the 510(k) pathway (K071328). In January 2022, (K211269), the system (software version 3.4) was classified as a neurosurgical tool with narrowed indications for use, including "to ablate, necrotize or coagulate intracranial soft tissue including brain structures (e.g., brain tumor, radiation necrosis and epileptic foci as identified by non-invasive and invasive neurodiagnostic testing, including imaging) through interstitial irradiation or thermal therapy in medicine and surgery in the discipline of neurosurgery with 800 nm through 1064 nm lasers." The device is not recommended for patients with medical conditions or implanted medical devices contraindicated for MRI and for patients whose physician determines that LITT or invasive surgical procedures in the brain are not acceptable. Data from compatible MRI sequences can be processed to relate imaging changes to relative changes in tissue temperature during therapy. The Visualase™ cooling applicator utilizes saline.

In April 2013, the NeuroBlate® System (Monteris Medical) received initial clearance for marketing by the FDA through the 510(k) pathway (K120561). As of August 2020, the system is indicated for use "to ablate, necrotize, or coagulate intracranial soft tissue, including brain structures (e.g., brain tumor and epileptic foci as identified by non-invasive and invasive neurodiagnostic testing, including imaging), through interstitial irradiation or thermal therapy in medicine and surgery in the discipline of neurosurgery with 1064 nm lasers" (K201056). The device is utilized for planning and monitoring of thermal therapy under MRI guidance, providing real-time thermographic analysis of selected MRI images. The NeuroBlate® system utilizes a laser probe with a sapphire capsule to promote prolonged, pulsed laser firing and a controlled cooling applicator employing pressurized CO₂.

On 04/25/2018, the FDA issued an FDA Alert on MR-Guided Laser Interstitial Thermal Therapy Devices with a letter to providers stating the FDA is currently evaluating data, which suggests that potentially inaccurate MR thermometry information can be displayed during treatment. “For example, MR parameters such as voxel size (measurement of the image resolution or detail) and MR image acquisition time (e.g., up to 8 seconds) may contribute to inaccurate MR thermometry readings and potential errors in the ablation assessment. In addition, MRgLITT devices may not account for the continued thermal spread of energy to the surrounding tissue (as the target ablation area returns to its baseline temperature), which may result in an underestimation of thermal damage.”

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

61736	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion (Effective 01/01/2022)
61737	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion (Effective 01/01/2022)

REFERENCES:

1. Barot N, Batra K, Zhang J, et al. Surgical outcomes between temporal, extratemporal epilepsies and hypothalamic hamartoma: systematic review and meta-analysis of MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy. J Neurol Neurosurg Psychiatry. Feb 2022; 93(2): 133-143.
2. Cobourn K, Fayed I, Keating R, Oluigbo C. Early outcomes of stereo electroencephalography followed by MR-guided laser interstitial thermal therapy: a paradigm for minimally invasive epilepsy surgery. Neurosurgical Focus. 2018 45 (3):1-9.
3. Epilepsy Foundation. <https://www.epilepsy.com/treatment/surgery/types/litt-thermal-ablation>. Accessed December 14, 2022.
4. Grewal SS, Alvi MA, Lu VM, et al. Magnetic Resonance-Guided Laser Interstitial Thermal Therapy Versus Stereotactic Radiosurgery for Medically Intractable Temporal Lobe Epilepsy: A Systematic Review and Meta-Analysis of Seizure Outcomes and Complications. World Neurosurg. 2019 Feb; 122: e32-e47.
5. Kang J, Sperling M. Magnetic Resonance Imaging-Guided Laser interstitial Thermal Therapy for Treatment of Drug-Resistant Epilepsy. 2017 14:176-181.

6. Kanner AM, Irving LT, Cajigas I, et al. Long-term seizure and psychiatric outcomes following laser ablation of mesial temporal structures. *Epilepsia*. Apr 2022; 63(4): 812-823.
7. Lagman C, Chung LK, Pelargos PE, et al. Laser neurosurgery: A systematic analysis of magnetic resonance-guided laser interstitial thermal therapies. *J Clin Neurosci*. 2017; 36: 20-26.
8. Lewis EC, Weil AG, Duchowny M, et al. MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy. *Epilepsia*. 2015; 56(10):1590-1598.
9. NeuroBlate® Systems website. <https://www.monteris.com/healthcare-professionals/neuroblate-procedure/> /. Accessed December 14, 2022.
10. Palmisciano P, Haider AS, Nwagwu CD, et al. Bevacizumab vs laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: a systematic review and meta-analysis. *J Neurooncol*. Aug 2021; 154(1): 13-23.
11. Rammo R, Scarpace L, Nagaraja T, Lee I. MR-guided laser interstitial thermal therapy in the treatment of recurrent intracranial meningioma's. *Lasers Surg Med*. 2019; 51(3):245-250.
12. Rao MS, Hargreaves EL, Khan AJ, et al. Magnetic resonance-guided laser ablation improves local control for post radiosurgery recurrence and/or radiation necrosis. *Neurosurgery*. 2014;74(6):658-667
13. Sankey EW, Grabowski MM, Srinivasan ES, et al. Time to Steroid Independence After Laser Interstitial Thermal Therapy vs Medical Management for Treatment of Biopsy-Proven Radiation Necrosis Secondary to Stereotactic Radiosurgery for Brain Metastasis. *Neurosurgery*. Jun 01 2022; 90(6): 684-690.
14. Shukla N, Ho A, Pendharkar A et al. Laser interstitial thermal therapy for the treatment of epilepsy: evidence to date. *Neuropsychiatr Dis Treat*. 2017; 13: 2469-2475.
15. UpToDate. Surgical Treatment of Epilepsy in Adults. Gregory D. Cascino M.D., Topic last updated November 11, 2022. Accessed December 14, 2022.
16. Visualase® Thermal Therapy Systems website. <https://www.medtronic.com/us-en/healthcare-professionals/products/neurological/laser-ablation/visualase.html>. Accessed December 14, 2022.
17. Waseem H, Vivas AC, Vale FL. MRI-guided laser interstitial thermal therapy for treatment of medically refractory non-lesional mesial temporal lobe epilepsy: Outcomes, complications, and current limitations: A review. *J Clin Neurosci*. 2017; 38: 1-7.

POLICY HISTORY:

Adopted for Blue Advantage, December 2021

Medical Policy Group, December 2021

Medical Policy Group, December 2022

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other

providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.